Sequana Medical announces presentation of pre-clinical proof of concept results of its Direct Sodium Removal (DSR) therapy for the management of volume overload in heart failure at the Annual Scientific Meeting of the Heart Failure Society of America (HFSA)

- 17/09/2018

Zurich, Switzerland: 17 September 2018 – Sequana Medical AG, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Direct Sodium Removal (“DSR”) therapy proof of concept study in pigs.

Sequana Medical’s proprietary DSR therapy is a novel approach to the management of volume overload in heart failure, a major clinical problem and a significant burden on healthcare systems. The body’s response to heart failure causes sodium levels to increase, which in turn leads to the body retaining more fluid. Sequana Medical’s DSR therapy involves the removal of sodium via diffusion from the peritoneal cavity by administering a sodium-free solution (the infusate) into the abdomen. The infusate and the extracted sodium are then removed, resulting in the elimination of sodium from the body. The body responds by eliminating the associated fluid via osmotic ultrafiltration and/or urination.

More info on Sequana’s website.